Claritas Announces Closing of Convertible Debenture Financing with Obsidian Global GP, LLC
October 19 2021 - 7:15AM
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V)
(the "
Company" or "
Claritas") is
pleased to announce that it has closed the first tranche of a
private placement offering (the “
Offering”) of
convertible debentures with Obsidian Global GP, LLC
(“
Obsidian”) for net proceeds of USD $930,000.
Highlights
-
Claritas received aggregate proceeds of approximately CAD
$1,247,000 (the “Aggregate Proceeds”) from the
closing.
-
Subject to the satisfaction of certain equity conditions,
entry into the relevant agreements between the parties, and TSXV
approval, a second tranche of the Offering may close in 90 days to
provide additional proceeds of USD $750,000 (“Tranche 2”) and a
third tranche may close 120 days following the closing of Tranche 2
to provide additional proceeds of approximately USD $1,250,000
(“Tranche 3”).
-
The Aggregate Proceeds will be allocated primarily to the
cost of the Phase 1 clinical study of R-107, as well as for general
corporate purposes.
Terms of the OfferingOn closing
of the first tranche of the Offering, the Company received gross
proceeds of USD $1,000,000 (the “Loan Amount”) and
issued to Obsidian a zero-interest, unsecured convertible debenture
(the “First Tranche Debenture”)
with a face value of USD $1,175,000 (the “Principal
Amount”). The transaction closed and the First Tranche
Debenture was issued effective October 14, 2021. From the Loan
Amount, B. Riley Financial, Inc., was paid a 7% cash commission in
the amount of USD $70,000. The First Tranche Debenture is
convertible at the option of Obsidian into common shares of the
Company (the “Common Shares”) at any time prior to
October 14, 2022 (the “First Tranche
Maturity Date”) at a conversion price of CAD
$0.355 (the “First Tranche Conversion
Price”). The First Tranche Debenture and any Common Shares
issuable upon conversion of the First Tranche Debenture will be
subject to a statutory hold period of four months ending on
February 15, 2022. Beginning on February 15, 2022, the Company is
obligated to begin making monthly amortization payments to Obsidian
in an amount equal to one-eighth of the outstanding Principal
Amount (the “First Tranche Amortization
Payments”). At the option of the Company, and subject to
the approval of the TSX Venture Exchange (the
“TSXV”), the First Tranche Amortization Payments
may be paid in Common Shares if certain equity conditions are met,
including minimum average daily trading volume of CAD $50,000 and a
market capitalization of at least CAD $15,000,000 (the
“Equity Conditions”). If the Company elects to pay
any First Tranche Amortization payments in Common Shares, such
Common Shares will be issued at a price equal to a 5% discount from
the lowest daily VWAP during the 10-days prior to the date on which
such issuance shall occur. As a condition of the Offering, Robert
Farrell, the Company’s Chairman, President and CEO, and Salzman
Group, Inc., the Company’s largest shareholder, pledged Common
Shares owned by them as collateral to secure 50% of the value of
the Principal Amount calculated as of the effective closing date of
the First Tranche Debenture, amounting to 2,742,849 pledged Common
Shares. In support of the transaction, the Company entered into
indemnification agreements with Mr. Farrell and Salzman Group, Inc.
under which, subject to TSXV approval, the Company will be
obligated to issue new Common Shares to each of them to replace any
of their pledged Common Shares that are realized as security by
Obsidian for the payment of the debenture as a result of any
uncured default by the Company under the terms of the First Tranche
Debenture.
“We are delighted to announce this transaction
with Obsidian, which will enable the Company to move forward with
and accelerate our Phase 1 clinical study of R-107,” said Robert
Farrell, Claritas’ President and CEO. “We expect to complete the
Phase 1 clinical study by Q1 next year, and thereafter we will
initiate a Phase 2a clinical study of R-107 in treatment of
pulmonary arterial hypertension (“PAH”), and seek
funding under a BARDA contract from the U.S. Department of Health
and Human Services for a Phase 2a clinical study of R-107 in
hospitalized patients diagnosed with COVID-19 related sepsis.”
The securities offered in the Offering have not
been, and will not be, registered under the U.S. Securities Act of
1933, as amended (the “U.S. Securities Act”) or
any U.S. state securities laws, and were not offered or sold in the
United States or to, or for the account or benefit of, United
States persons absent registration or any applicable exemption from
the registration requirements of the U.S. Securities Act and
applicable U.S. state securities laws. This news release shall not
constitute an offer to sell or the solicitation of an offer to buy
securities in the United States, nor shall there be any sale of
these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful.About Claritas
PharmaceuticalsClaritas Pharmaceuticals, Inc. is a
clinical stage biopharmaceutical company focused on developing and
commercializing therapies for patients with significant unmet
medical needs. Claritas leverages its expertise to find solutions
that will improve health outcomes and dramatically improve people's
lives.
- Website
Home: https://claritaspharma.com/
- News and
Insights: https://claritaspharma.com/news/
-
Investors: https://claritaspharma.com/investors
Cautionary StatementsNeither
TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
This press release may contain certain
forward-looking information and statements ("forward-looking
information") within the meaning of applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation in respect of the Company’s planned clinical
study of R-107, the possibility of undertaking and closing Tranche
2 and/or Tranche 3, regulatory approval prospects (including
approval of the indemnification agreement and the shares to be
issued thereunder), intellectual property objectives, and other
statements containing the words "believes", "anticipates", "plans",
"intends", "will", “may”, "should", "expects", "continue",
"estimate", "forecasts" and other similar expressions. Readers are
cautioned to not place undue reliance on forward-looking
information. Actual results and developments may differ materially
from those contemplated by these statements depending on, among
other things, the risk that future clinical studies may not proceed
as expected or may produce unfavorable results or that the Company
may not complete Tranche 2 or Tranche 3. Unless required by
applicable law, Claritas undertakes no obligation to comment on
analyses, expectations or statements made by third parties, its
securities, or financial or operating results (as applicable).
Although Claritas believes that the expectations reflected in
forward-looking information in this press release are reasonable,
such forward-looking information has been based on expectations,
factors and assumptions concerning future events which may prove to
be inaccurate and are subject to numerous risks and uncertainties,
certain of which are beyond Claritas’ control. The forward-looking
information contained in this press release is expressly qualified
by this cautionary statement and is made as of the date hereof.
Claritas disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise.
Contact InformationRobert
FarrellPresident, CEO(888) 861-2008info@claritaspharma.com
Kalytera Therapeutics (TSXV:KLY)
Historical Stock Chart
From Nov 2024 to Dec 2024
Kalytera Therapeutics (TSXV:KLY)
Historical Stock Chart
From Dec 2023 to Dec 2024